Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives

Zappaterra, 2012, The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond, Cell. Mol. Life Sci., 69, 2863, 10.1007/s00018-012-0957-x Golde, 2009, The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease, Mol. Neurodegener., 4, 8, 10.1186/1750-1326-4-8 Jack, 2011, Introduction to the recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 257, 10.1016/j.jalz.2011.03.004 Feneberg, 2012, Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration, J. Lab. Med., 36, 3 Knowles, 2014, The amyloid state and its association with protein misfolding diseases, Nat. Rev. Mol. Cell Biol., 15, 384, 10.1038/nrm3810 Jellinger, 2009, Recent advances in our understanding of neurodegeneration, J. Neural Transm., 116, 1111, 10.1007/s00702-009-0240-y Seltman, 2012, Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management, CNS Drugs, 26, 841, 10.2165/11640070-000000000-00000 Savica, 2013, Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism, JAMA Neurol., 70, 859, 10.1001/jamaneurol.2013.114 Rabinovici, 2010, Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management, CNS Drugs, 24, 375, 10.2165/11533100-000000000-00000 Sieben, 2012, The genetics and neuropathology of frontotemporal lobar degeneration, Acta Neuropathol., 124, 353, 10.1007/s00401-012-1029-x Mackenzie, 2011, A harmonized classification system for FTLD–TDP pathology, Acta Neuropathol., 122, 111, 10.1007/s00401-011-0845-8 Simonsen, 2007, A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia, Dement. Geriatr. Cogn. Disord., 24, 434, 10.1159/000110576 Mattsson, 2008, Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia, Mol. Med. Rep., 1, 757 Rüetschi, 2005, Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF, Exp. Neurol., 196, 273, 10.1016/j.expneurol.2005.08.002 Constantinescu, 2010, Proteomic profiling of cerebrospinal fluid in parkinsonian disorders, Parkinsonism Relat. Disord., 16, 545, 10.1016/j.parkreldis.2010.06.011 Davidsson, 2002, Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins, Brain Res. Mol. Brain Res., 109, 128, 10.1016/S0169-328X(02)00549-1 Hansson, 2004, Validation of a prefractionation method followed by two-dimensional electrophoresis — applied to cerebrospinal fluid proteins from frontotemporal dementia patients, Proteome Sci., 2, 7, 10.1186/1477-5956-2-7 Jahn, 2011, Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers, PLoS One, 6, e26540, 10.1371/journal.pone.0026540 Janssens, 2013, Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders, Hum. Mol. Genet., 22, R77, 10.1093/hmg/ddt349 Steinacker, 2008, TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Arch. Neurol., 65, 1481, 10.1001/archneur.65.11.1481 Feneberg, 2014, Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases, Amyotroph. Lateral Scler. Frontotemporal Degener, 1 Suárez-Calvet, 2014, Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation, J. Neurol. Neurosurg. Psychiatry, 85, 684, 10.1136/jnnp-2013-305972 Nguyen, 2013, Progranulin: at the interface of neurodegenerative and metabolic diseases, Trends Endocrinol. Metab., 24, 597, 10.1016/j.tem.2013.08.003 Ghidoni, 2008, Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration, Neurology, 71, 1235, 10.1212/01.wnl.0000325058.10218.fc Van Damme, 2008, Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival, J. Cell Biol., 181, 37, 10.1083/jcb.200712039 Philips, 2010, Microglial upregulation of progranulin as a marker of motor neuron degeneration, J. Neuropathol. Exp. Neurol., 69, 1191, 10.1097/NEN.0b013e3181fc9aea Clavaguera, 2013, “Prion-like” templated misfolding in tauopathies, Brain Pathol., 23, 342, 10.1111/bpa.12044 Riedl, 2014, Frontotemporal lobar degeneration: current perspectives, Neuropsychiatr. Dis. Treat., 10, 297 Irwin, 2013, Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease, Front. Aging Neurosci., 5, 6, 10.3389/fnagi.2013.00006 van Harten, 2011, Tau and p-tau as CSF biomarkers in dementia: a meta-analysis, Clin. Chem. Lab. Med., 49, 353, 10.1515/CCLM.2011.086 Luk, 2012, Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies, J. Neurochem., 123, 396, 10.1111/j.1471-4159.2012.07911.x Blennow, 2010, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat. Rev. Neurol., 6, 131, 10.1038/nrneurol.2010.4 Mollenhauer, 2011, α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, Lancet Neurol., 10, 230, 10.1016/S1474-4422(11)70014-X Mandelkow, 2012, Biochemistry and cell biology of tau protein in neurofibrillary degeneration, Cold Spring Harb. Perspect. Med., 2, a006247, 10.1101/cshperspect.a006247 Hampel, 2004, Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study, Arch. Gen. Psychiatry, 61, 95, 10.1001/archpsyc.61.1.95 Buerger, 2002, Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231, Arch. Neurol., 59, 1267, 10.1001/archneur.59.8.1267 Selkoe, 2001, Alzheimer's disease: genes, proteins, and therapy, Physiol. Rev., 81, 741, 10.1152/physrev.2001.81.2.741 Portelius, 2011, A novel pathway for amyloid precursor protein processing, Neurobiol. Aging, 32, 1090, 10.1016/j.neurobiolaging.2009.06.002 Arnold, 2000, Quantitative neurohistological features of frontotemporal degeneration, Neurobiol. Aging, 21, 913, 10.1016/S0197-4580(00)00173-1 Mollenhauer, 2007, Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?, J. Neural Transm., 114, 919, 10.1007/s00702-007-0629-4 Bibl, 2007, Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias, Mol. Psychiatry, 12, 671, 10.1038/sj.mp.4001967 Bibl, 2007, Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations, J. Neural Transm., 114, 621, 10.1007/s00702-006-0618-z Bibl, 2012, Cerebrospinal fluid amyloid-β 2–42 is decreased in Alzheimer's, but not in frontotemporal dementia, J. Neural Transm., 119, 805, 10.1007/s00702-012-0801-3 Bibl, 2008, CSF amyloid-β 1–38 and 1–42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction, Proteomics Clin. Appl., 2, 1548, 10.1002/prca.200800006 Bibl, 2011, Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias, Dement. Geriatr. Cogn. Disord., 31, 37, 10.1159/000322370 Gabelle, 2011, Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia, J. Alzheimers Dis., 26, 553, 10.3233/JAD-2011-110515 Steinacker, 2009, Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration, J. Neural Transm., 116, 1169, 10.1007/s00702-009-0271-4 Hansson, 2009, Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients, J. Alzheimers Dis., 16, 389, 10.3233/JAD-2009-0966 Pijnenburg, 2007, Decreased cerebrospinal fluid amyloid beta (1–40) levels in frontotemporal lobar degeneration, J. Neurol. Neurosurg. Psychiatry, 78, 735, 10.1136/jnnp.2006.105064 Verwey, 2009, Quantification of amyloid-beta 40 in cerebrospinal fluid, J. Immunol. Methods, 348, 57, 10.1016/j.jim.2009.06.011 Verwey, 2010, Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects, J. Alzheimers Dis., 20, 445, 10.3233/JAD-2010-1392 Gloeckner, 2008, Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia, J. Alzheimers Dis., 14, 17, 10.3233/JAD-2008-14102 Nutu, 2013, Aβ1–15/16 as a potential diagnostic marker in neurodegenerative diseases, Neuromolecular Med., 15, 169, 10.1007/s12017-012-8208-8 Portelius, 2010, A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease, Alzheimers Res. Ther., 2, 7, 10.1186/alzrt30 Perneczky, 2011, CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease, Neurology, 77, 35, 10.1212/WNL.0b013e318221ad47 Alcolea, 2014, Relationship between β-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease, J. Alzheimers Dis., 42, 157, 10.3233/JAD-140240 Kimura, 1999, Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease, Neurosci. Lett., 273, 137, 10.1016/S0304-3940(99)00631-X Alexopoulos, 2012, Interrelations between CSF soluble AβPPβ, amyloid-β 1–42, SORL1, and tau levels in Alzheimer's disease, J. Alzheimers Dis., 28, 543, 10.3233/JAD-2011-110983 Sjögren, 2001, The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process, Dement. Geriatr. Cogn. Disord., 12, 257, 10.1159/000051268 Petzold, 2005, Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss, J. Neurol. Sci., 233, 183, 10.1016/j.jns.2005.03.015 Shea, 2008, Regulation of neurofilament dynamics by phosphorylation, Eur. J. Neurosci., 27, 1893, 10.1111/j.1460-9568.2008.06165.x Lingor, 2012, Axonal degeneration as a therapeutic target in the CNS, Cell Tissue Res., 349, 289, 10.1007/s00441-012-1362-3 Brettschneider, 2006, Axonal damage markers in cerebrospinal fluid are increased in ALS, Neurology, 66, 852, 10.1212/01.wnl.0000203120.85850.54 Tortelli, 2012, Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression, Eur. J. Neurol., 19, 1561, 10.1111/j.1468-1331.2012.03777.x Rosengren, 1999, Neurofilament protein levels in CSF are increased in dementia, Neurology, 52, 1090, 10.1212/WNL.52.5.1090 Sjögren, 2000, Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD, Neurology, 54, 1960, 10.1212/WNL.54.10.1960 Sjögren, 2001, Pathophysiological aspects of frontotemporal dementia—emphasis on cytoskeleton proteins and autoimmunity, Mech. Ageing Dev., 122, 1923, 10.1016/S0047-6374(01)00303-7 de Jong, 2007, CSF neurofilament proteins in the differential diagnosis of dementia, J. Neurol. Neurosurg. Psychiatry, 78, 936, 10.1136/jnnp.2006.107326 Landqvist Waldö, 2013, Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia, BMC Neurol., 13, 54, 10.1186/1471-2377-13-54 Scherling, 2014, Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration, Ann. Neurol., 75, 116, 10.1002/ana.24052 Pijnenburg, 2007, CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls, Dement. Geriatr. Cogn. Disord., 23, 225, 10.1159/000099473 Constantinescu, 2010, Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders, Parkinsonism Relat. Disord., 16, 142, 10.1016/j.parkreldis.2009.07.007 Holmberg, 2001, CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes, Parkinsonism Relat. Disord., 8, 23, 10.1016/S1353-8020(00)00083-3 Holmberg, 1998, Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease, Mov. Disord., 13, 70, 10.1002/mds.870130116 Hall, 2012, Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders, Arch. Neurol., 69, 1445, 10.1001/archneurol.2012.1654 Bech, 2012, Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes, Parkinsonism Relat. Disord., 18, 69, 10.1016/j.parkreldis.2011.08.012 Abdo, 2007, CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease, Neurobiol. Aging, 28, 742, 10.1016/j.neurobiolaging.2006.03.010 Brettschneider, 2006, The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease, Dement. Geriatr. Cogn. Disord., 21, 291, 10.1159/000091436 Brettschneider, 2006, Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes, Mov. Disord., 21, 2224, 10.1002/mds.21124 Ash, 2013, Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS, Neuron, 77, 639, 10.1016/j.neuron.2013.02.004 Su, 2014, Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS, Neuron, 83, 1043, 10.1016/j.neuron.2014.07.041 Kimura, 2010, Regulatory mechanisms involved in the control of ubiquitin homeostasis, J. Biochem., 147, 793, 10.1093/jb/mvq044 Hegde, 2011, Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease, Biochim. Biophys. Acta, 1809, 128, 10.1016/j.bbagrm.2010.07.006 Wang, 1991, Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid, Acta Neuropathol., 82, 6, 10.1007/BF00310917 Kudo, 1994, Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels, Brain Res., 639, 1, 10.1016/0006-8993(94)91757-4 Blennow, 1994, Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia, Int. Psychogeriatr., 6, 13, 10.1017/S1041610294001584 Iqbal, 2005, Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers, Ann. Neurol., 58, 748, 10.1002/ana.20639 Kandimalla, 2011, Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients, Neurosci. Lett., 487, 134, 10.1016/j.neulet.2010.06.075 Oeckl, 2014, Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration, J. Proteome Res., 13, 4518, 10.1021/pr5006058 Steinacker, 2010, Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt–Jakob disease, Proteomics, 10, 81, 10.1002/pmic.200900246 Manaka, 1992, Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt–Jakob disease, Neurosci. Lett., 139, 47, 10.1016/0304-3940(92)90854-Z Kowalski, 2012, The role of deubiquitinating enzymes in synaptic function and nervous system diseases, Neural. Plast., 2012, 892749, 10.1155/2012/892749 Mondello, 2014, CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders, Parkinsonism Relat. Disord., 20, 382, 10.1016/j.parkreldis.2014.01.011 Irwin, 2013, Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies, Nat. Rev. Neurosci., 14, 626, 10.1038/nrn3549 Spies, 2009, Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders, J. Alzheimers Dis., 16, 363, 10.3233/JAD-2009-0955 Parnetti, 2011, Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias, Mov. Disord., 26, 1428, 10.1002/mds.23670 Wang, 2012, Phosphorylated α-synuclein in Parkinson's disease, Sci. Transl. Med., 4, 121ra20, 10.1126/scitranslmed.3002566 Foulds, 2012, Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and dementia with Lewy bodies, Neurobiol. Dis., 45, 188, 10.1016/j.nbd.2011.08.003 Aerts, 2012, CSF α-synuclein does not differentiate between parkinsonian disorders, Neurobiol. Aging, 33, 430.e1-3, 10.1016/j.neurobiolaging.2010.12.001 Tokuda, 2010, Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 75, 1766, 10.1212/WNL.0b013e3181fd613b Hong, 2010, DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008 Cookson, 2012, Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways, Cold Spring Harb. Perspect. Med., 2, a009415, 10.1101/cshperspect.a009415 Salvesen, 2012, The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes, Parkinsonism Relat. Disord., 18, 899, 10.1016/j.parkreldis.2012.03.013 Flynn, 2013, SOD2 in mitochondrial dysfunction and neurodegeneration, Free Radic. Biol. Med., 62, 4, 10.1016/j.freeradbiomed.2013.05.027 Aoyama, 2000, Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases, Ann. Neurol., 47, 524, 10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.0.CO;2-5 Cantuti-Castelvetri, 2002, Expression and activity of antioxidants in the brain in progressive supranuclear palsy, Brain Res., 930, 170, 10.1016/S0006-8993(02)02244-8 Ridolfi, 2013, The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia, Clin. Dev. Immunol., 2013, 939786, 10.1155/2013/939786 Galimberti, 2006, Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration, Neurology, 66, 146, 10.1212/01.wnl.0000191324.08289.9d Galimberti, 2008, Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration, J. Neurol., 255, 539, 10.1007/s00415-008-0737-6 Sjögren, 2004, Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications, J. Neurol. Neurosurg. Psychiatry, 75, 1107, 10.1136/jnnp.2003.019422 Comi, 2010, Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline, J. Alzheimers Dis., 19, 1143, 10.3233/JAD-2010-1309 Rentzos, 2006, IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia, J. Geriatr. Psychiatry Neurol., 19, 114, 10.1177/0891988706286226 Hu, 2010, Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment, Acta Neuropathol., 119, 669, 10.1007/s00401-010-0667-0 Yamada, 1994, Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy, Acta Neurol. Scand., 89, 42, 10.1111/j.1600-0404.1994.tb01631.x Olsson, 2013, The glial marker YKL-40 is decreased in synucleinopathies, Mov. Disord., 28, 1882, 10.1002/mds.25589 Hu, 2010, Novel CSF biomarkers for frontotemporal lobar degenerations, Neurology, 75, 2079, 10.1212/WNL.0b013e318200d78d Tsuboi, 2002, Hepatocyte growth factor in cerebrospinal fluid in neurologic disease, Acta Neurol. Scand., 106, 99, 10.1034/j.1600-0404.2002.01125.x Sáez-Valero, 2003, Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease, J. Neurosci. Res., 72, 132, 10.1002/jnr.10554 Botella-López, 2006, Reelin expression and glycosylation patterns are altered in Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 103, 5573, 10.1073/pnas.0601279103 Green, 1997, Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia, Neurosci. Lett., 235, 5, 10.1016/S0304-3940(97)00701-5 Maeck, 2002, Abeta peptide 1–42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia, Neurosci. Lett., 333, 33, 10.1016/S0304-3940(02)00968-0 Petzold, 2003, Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease, Neurosci. Lett., 336, 167, 10.1016/S0304-3940(02)01257-0 Reiber, 2001, Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs, J. Neurol. Sci., 184, 101, 10.1016/S0022-510X(00)00501-3 del Campo, 2012, Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update, Biomark. Med, 6, 419, 10.2217/bmm.12.46 Blasko, 2006, Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias, Dement. Geriatr. Cogn. Disord., 21, 9, 10.1159/000089137 Galimberti, 2009, MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels, J. Alzheimers Dis., 17, 125, 10.3233/JAD-2009-1019 Rentzos, 2006, Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia, J. Neurol. Sci., 249, 110, 10.1016/j.jns.2006.05.063 Süssmuth, 2010, Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes, Mov. Disord., 25, 1284, 10.1002/mds.22895 Sjögren, 2000, CSF levels of tau, beta-amyloid(1–42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J. Neural Transm., 107, 563, 10.1007/s007020070079 Edvinsson, 1993, Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration, Dementia, 4, 167 Iadarola, 1989, Decrease in a proenkephalin peptide in cerebrospinal fluid in Huntington's disease and progressive supranuclear palsy, Brain Res., 479, 397, 10.1016/0006-8993(89)91648-X Ernst, 2010, Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation, J. Neuroimmunol., 221, 62, 10.1016/j.jneuroim.2010.02.004 Brettschneider, 2004, Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus?, J. Neurol. Neurosurg. Psychiatry, 75, 1614, 10.1136/jnnp.2003.026013 Litvan, 1992, CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy, Acta Neurol. Scand., 86, 204, 10.1111/j.1600-0404.1992.tb05067.x Minthon, 1996, Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia, Alzheimer Dis. Assoc. Disord., 10, 197, 10.1097/00002093-199601040-00005 Palumbo, 2008, Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?, Funct. Neurol., 23, 93 Yasui, 2006, CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration, J. Neurol. Sci., 250, 120, 10.1016/j.jns.2006.08.004 Minthon, 1997, Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia, Dement. Geriatr. Cogn. Disord., 8, 232, 10.1159/000106636 Klafki, 2009, Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form, J. Alzheimers Dis., 18, 613, 10.3233/JAD-2009-1167 Brettschneider, 2006, Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases, Neurosci. Lett., 404, 347, 10.1016/j.neulet.2006.06.011 Diamandis, 2004, Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia, Clin. Biochem., 37, 230, 10.1016/j.clinbiochem.2003.11.012 Ikeuchi, 2010, Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease, Dement. Geriatr. Cogn. Disord., 30, 28, 10.1159/000315539 Miyajima, 2013, Leucine-rich α2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex, PLoS One, 8, e74453, 10.1371/journal.pone.0074453 Ernst, 2007, Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation, J. Neuroimmunol., 189, 169, 10.1016/j.jneuroim.2007.07.009 Mulder, 2009, CSF levels of PSA and PSA–ACT complexes in Alzheimer's disease, Ann. Clin. Biochem., 46, 477, 10.1258/acb.2009.009130 Le Pera, 2012, Contribution of cerebrospinal fluid thymosin β4 levels to the clinical differentiation of Creutzfeldt–Jakob disease, Arch. Neurol., 69, 868, 10.1001/archneurol.2011.3558 Sorensen, 2013, Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease, J. Alzheimers Dis., 37, 379, 10.3233/JAD-122410 Yamada, 1993, Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease, Jpn. J. Psychiatry Neurol., 47, 631